Immunai Overview
Immunai is developing a proprietary data set of multi-omic, immune-centric peripheral tissue analyses. The company's advanced analytics and data-visualization interface allows researchers to comprehensively view and interrogate data and to derive novel conclusions on the underlying mechanisms of disease. The platform is currently being used to develop and refine cell therapies for neuroblastoma in conjunction with the Baylor College of Medicine.
Cumulative Funding Raised Over Time ($)
$60.0MFeb 2021
$80.0MMay 2020
$295.0MOct 2021
Latest News
growth-positive
AI biotech expands partnership after uncovering novel immune target with its machine learning platform.
Immunai, an Israeli AI biotech company, has entered into a new agreement with AstraZeneca to develop a novel therapeutic target for inflammatory bowel disease (IBD). This partnership leverages Immunais Immunodynamics Engine (IDE) and its proprietary immune cell atlas, AMICA, which integrates single-cell multi-omics data with machine learning. AstraZeneca will have exclusive rights to develop and commercialize therapeutics aimed at the newly identified target, with Immunai receiving an upfront payment and potential earnings of up to $85 million based on development milestones. This agreement marks a significant milestone in Immunais ongoing collaboration with AstraZeneca, which began in 2022 and included an $18 million investment in 2024 to enhance oncology clinical trials.
PartnersInvestment
growth-positive
Immunai and Teva launch multi-tear AI collaboration for smarter drug development | CTech
Immunai, an AI biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance clinical decision-making in Tevas immunology trials using Immunais proprietary immune cell atlas and AI model. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This reflects Immunais ongoing efforts to streamline drug development processes. The collaboration is expected to provide insights into patient responses and treatment mechanisms, optimizing clinical trials and improving patient outcomes. Immunai recently announced a similar collaboration with AstraZeneca, valued at $18 million. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021.
Partners
growth-positive
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.
Immunai, an AI biotech company specializing in mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance Tevas Immunology and Immuno-oncology programs by leveraging Immunais immune cell atlas and AI model to improve clinical decision-making. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This partnership reflects Immunais ongoing efforts to streamline drug development and deliver new therapies to patients. Additionally, Immunai recently announced a collaboration with AstraZeneca, valued at $18 million, to enhance cancer drug trials. Immunai has raised a total of $295 million, including a $215 million Series B round in 2021, with a valuation of just over $1 billion.
Partners
growth-positive
The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging the Israeli biotech unicorn’s AI model of the immune system.
Israeli biotech startup Immunai has announced a multi-year collaboration with AstraZeneca, focusing on clinical decision-making and leveraging Immunais AI model of the immune system. Immunai will receive $18 million for the initial phase, with AstraZeneca having the option to extend the collaboration. The partnership aims to improve clinical trial success rates and R&D productivity. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021. This collaboration is part of AstraZenecas broader strategy to use AI in drug discovery and development.
PartnersInvestment
growth-positive
The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.
Israeli company Immunai, which develops AI-based tools for drug discovery, has entered into a strategic agreement with AstraZeneca. The deal is initially worth $18 million, but its significance lies in the planned multi-year collaboration between the two companies. Immunais platform, which models the human immune system, aims to improve the efficiency of drug development. The company has raised $300 million to date, including $215 million in a single round in 2021, and currently employs 170 people. AstraZenecas chief data scientist highlighted the potential of Immunais platform to enhance their R&D strategy.
PartnersInvestment
| Sector | Health Tech & Life Sciences |
Funding
| Total funding | $295M |
| Last funding | $215M |
| Stage | B |
| Rounds | 3 |
| Investors | 14 |
Team Members
3
Employees: 51-200
Web & Social Links
| Website | www.immunai.com |
| Careers | Careers page |
Locations
Tel Aviv, Israel
430 E 29th St, New York, NY, USA
Photos & Videos
2 item(s)
Immunai Business
Business models
B2B
Product stage
R&D
Employees
51-200
Sector
Business SoftwareIT, R&D & Data SolutionsData Analysis & Decision SupportHealth Tech & Life SciencesDigital HealthcareMedical Decision SupportPharma & Medical BiotechnologyDrugs Discovery & DevelopmentTarget Customer
Healthcare & Life SciencesHealthcareLaboratoriesProvidersLife SciencesPharmaceuticalsCore Technology
Artificial IntelligenceDeep LearningMachine LearningTags (15)
clinical-trialsimmunotherapyunicorn-2021digital-healthcarehospitalsimmunologydata-analyticsactionable-insightspharma-companiescancerautoimmune-diseasesartificial-intelligencemachine-learningdeep-learningcellsImmunai Financials
$295M
Total funding
Undisclosed
Capital raised
$215M
Last funding
B
Funding stage
3
Total rounds
14
Investors
Cumulative Funding Raised Over Time ($)
$60.0MFeb 2021
$80.0MMay 2020
$295.0MOct 2021
Private Equity Funding
B Round
Oct 2021
$215M
Koch Disruptive Technologies (Lead)
,
ICON, 8VC, Piedmont Venture Capital, Alexandria Venture Investments, Gefen Capital, Talis Capital
A Round
Feb 2021
$60M
Duquesne Family Office, TLV Partners, Schusterman Family Investments , Catalio Capital Management, Meron Capital, Viola Ventures, Gefen Capital, Dexcel Pharma
Seed
May 2020
$20M
TLV Partners (Lead)
,
Gefen Capital, Viola Ventures
Mergers & Acquisitions
MNAEvent
Aug 2021
Undisclosed
MNAEvent
Mar 2021
Undisclosed
Immunai Lifecycle
Cumulative Funding Raised Over Time
$60.0MFeb 2021
$80.0MMay 2020
$295.0MOct 2021
All Events
B Round
Oct 2021
$215M
Koch Disruptive Technologies (Lead)
,
ICON, 8VC, Piedmont Venture Capital, Alexandria Venture Investments, Gefen Capital, Talis Capital
A Round
Feb 2021
$60M
Duquesne Family Office, TLV Partners, Schusterman Family Investments , Catalio Capital Management, Meron Capital, Viola Ventures, Gefen Capital, Dexcel Pharma
Seed
May 2020
$20M
TLV Partners (Lead)
,
Gefen Capital, Viola Ventures
MNAEvent
Aug 2021
Undisclosed
MNAEvent
Mar 2021
Undisclosed
Immunai News
13 articles
growth-positive
AI biotech expands partnership after uncovering novel immune target with its machine learning platform.
Immunai, an Israeli AI biotech company, has entered into a new agreement with AstraZeneca to develop a novel therapeutic target for inflammatory bowel disease (IBD). This partnership leverages Immunais Immunodynamics Engine (IDE) and its proprietary immune cell atlas, AMICA, which integrates single-cell multi-omics data with machine learning. AstraZeneca will have exclusive rights to develop and commercialize therapeutics aimed at the newly identified target, with Immunai receiving an upfront payment and potential earnings of up to $85 million based on development milestones. This agreement marks a significant milestone in Immunais ongoing collaboration with AstraZeneca, which began in 2022 and included an $18 million investment in 2024 to enhance oncology clinical trials.
PartnersInvestment
growth-positive
Immunai and Teva launch multi-tear AI collaboration for smarter drug development | CTech
Immunai, an AI biotech company specializing in mapping the human immune system, has announced a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance clinical decision-making in Tevas immunology trials using Immunais proprietary immune cell atlas and AI model. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This reflects Immunais ongoing efforts to streamline drug development processes. The collaboration is expected to provide insights into patient responses and treatment mechanisms, optimizing clinical trials and improving patient outcomes. Immunai recently announced a similar collaboration with AstraZeneca, valued at $18 million. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021.
Partners
growth-positive
The partnership will utilize Immunai’s cutting-edge immune system mapping tools to enhance precision in immunology and oncology trials.
Immunai, an AI biotech company specializing in mapping the human immune system, has entered a multi-year collaboration with Teva Pharmaceuticals. This partnership aims to enhance Tevas Immunology and Immuno-oncology programs by leveraging Immunais immune cell atlas and AI model to improve clinical decision-making. The collaboration will focus on drug mechanism of action, dose selection, and biomarker analyses. This partnership reflects Immunais ongoing efforts to streamline drug development and deliver new therapies to patients. Additionally, Immunai recently announced a collaboration with AstraZeneca, valued at $18 million, to enhance cancer drug trials. Immunai has raised a total of $295 million, including a $215 million Series B round in 2021, with a valuation of just over $1 billion.
Partners
growth-positive
The collaboration will focus on clinical decision-making, including dose selection, elucidating mechanisms of action, patient responder vs. non-responder analysis, and biomarker identification, by leveraging the Israeli biotech unicorn’s AI model of the immune system.
Israeli biotech startup Immunai has announced a multi-year collaboration with AstraZeneca, focusing on clinical decision-making and leveraging Immunais AI model of the immune system. Immunai will receive $18 million for the initial phase, with AstraZeneca having the option to extend the collaboration. The partnership aims to improve clinical trial success rates and R&D productivity. Immunai, which employs 170 people, raised a $215 million Series B at a valuation of just over $1 billion in 2021. This collaboration is part of AstraZenecas broader strategy to use AI in drug discovery and development.
PartnersInvestment
growth-positive
The agreement is worth an initial $18 million to Immunai, developer of an AI-based model for making drug development more efficient.
Israeli company Immunai, which develops AI-based tools for drug discovery, has entered into a strategic agreement with AstraZeneca. The deal is initially worth $18 million, but its significance lies in the planned multi-year collaboration between the two companies. Immunais platform, which models the human immune system, aims to improve the efficiency of drug development. The company has raised $300 million to date, including $215 million in a single round in 2021, and currently employs 170 people. AstraZenecas chief data scientist highlighted the potential of Immunais platform to enhance their R&D strategy.
PartnersInvestment
growth-positive
Immunai announces a $215M Series B as its 'immune cell atlas' matures
Biotech startup Immunai has raised $215 million in a series B funding round, bringing its total funding to $295 million. The company has been building a large data set of clinical immunological information to map out how the immune system functions. It uses machine learning to identify drug targets, predict patient responses, and develop cell therapies. Immunais data set, called the Annotated Multi-omic Immune Cell Atlas (AMICA), is claimed to be the largest in the world. The funding will be used to expand the workforce, enrich the data set, and strengthen the companys infrastructure. Immunai has collaborated with over 30 companies and academic institutions and has made two major acquisitions to accelerate the growth of its database.
Investment
growth-positive
Nebion becomes a subsidiary of New-York based Immunai
Immunai has announced the acquisition of Swiss bioinformatics company Nebion to expand its discovery and drug development capabilities. Nebion will become a wholly-owned subsidiary operating under the same name. The acquisition will allow Immunai to incorporate Nebions curated public datasets to improve its machine learning models and find drug targets. Immunai has also brought on renowned executives, including Robert Langer, Jacques Banchereau, and Mark Jacobstein. Immunai has raised over $90M in capital to date.
Acquisition
growth-positive
Creating a vital map of the human immune system
Immunai, a Tel Aviv-based company, is mapping the human immune system to understand how it fights diseases and develop new drugs. The company uses a granular map of the immune system to identify patterns and develop therapies. Immunai is working with CAR-T cells for its initial treatments and has acquired Dropprint Genomics to enhance its drug development capabilities. The company has raised $80 million in funding and has a multidisciplinary team of experts. Immunai aims to study immune-related diseases together to find connections and accelerate learning. The company believes that mapping the immune system is only the first step and plans to use the map to reprogram the immune system. Immunai has been recognized as one of the most promising companies and is focused on driving change through data and software.
PartnersInvestment
growth-positive
Immunai Acquires Dropprint Genomics and Strengthens Leadership Team with Experts in Immunology to Expand Target Discovery Capabilities
Immunai, a biotech company, has announced its acquisition of Dropprint Genomics, a single-cell genomics software company. The acquisition will support Immunais work in single cell functional genomics and the development of new therapies. Immunai has also expanded its leadership team and scientific advisory board. The company has raised $80M in funding from various investors.
AcquisitionExpand
growth-positive
Immunai raises $60M as it expands from improving immune therapies to discovering new ones, too
Biotech startup Immunai has raised $60 million in Series A funding, bringing its total raised to over $80 million. The company has established the largest database in the world for single cell immunity characteristics and has used its machine learning-powered platform to enhance existing immunotherapies. With the new funding, Immunai plans to expand into the development of new therapies based on its data and ML. The company uses a multiomic approach to analyze different types of biological data. Immunai has partnerships with leading immunological research organizations and aims to create new drugs based on its understanding of the human immune profile.
Investment
growth-positive
Immunai joins 10x Genomics program to boost drug development
Immunai, a startup specializing in artificial intelligence and single-cell biology, has partnered with 10x Genomics to provide drugmakers with a better view of how a patients immune system responds to therapy. The partnership allows Immunai to become one of the first certified service providers for 10x Genomics in North America. By combining their technologies, the two companies aim to improve the understanding of the immune system and identify new potential drug combinations. Immunai, which emerged from stealth mode with $20 million in seed funding, has customers including drug companies and academic research institutions. The companys technology offers a more detailed look at cells and allows for the analysis of single-cell behavior on a larger scale.
Partners
growth-positive
The startup databasing our immune system
Immunai is building a database to profile the interactions between immune system cells in states of health and disease. The company aims to develop drugs based on immune system manipulation in a more efficient and customized way. It generates revenue by providing access to its database to pharmaceutical companies and is expected to announce a joint development agreement with a major pharmaceutical company. Immunais technology is based on an AI system and unique capabilities for profiling single-cell activity. The company has raised $20 million from Viola Ventures and TLV Partners and has 30 employees in Tel Aviv.
PartnersInvestment
growth-positive
Immune system mapping co Immunai raises $20m
Immunai, an Israeli-US personalized therapeutics company, has raised $20 million in funding for the development of its system for adapting treatments and accelerating drug development. The company uses machine learning and genetic sequencing technology to build a broad immunological database, aiming to make the effect of cancer treatments targeting the immune system more predictable. The funding round was led by Viola Ventures and TLV Partners. Immunai employs over 30 people in Tel Aviv and New York and collaborates with leading hospitals and pharmaceutical companies.
InvestmentExpand
Immunai Team
Employee Info
| Employees (range) | 51-200 |
| Exact count | 192 |
| Team members | 3 |
Similar Companies
Similar companies data is computed dynamically and not stored in the entity profile. This section requires implementing a similarity query (e.g. by classification overlap, sector, district).
This entity has 18 classification IDs that could be used for matching.
Immunai Internal
Recent Updates
No update log entries.
Note: Free-text notes visible in the original Finder "Internal" tab are not present in the imported profile data. Only the update audit log is available.
Admin Info
| Confidence | 91/100 |
| Missing | markets, not claimed |
| BI Verification | Maor Perlov |
| Registrar ID | 515981934 |
| Crunchbase | immunai |
| Creator | Yotam Maman |
| Creator email | yotamm1988@gmail.com |
| Last updater | Maor Perlov |
| Updater email | maorperlov@gmail.com |
| Last update | 2021-10-31T00:00:00.000Z |
| Created | 2019-10-02T00:00:00.000Z |